OTR's 'Molecular Glue' Aims to Revive Failed Cancer Drugs

In a lab outside Boston, scientists at OTR Therapeutics are sifting through the pharmaceutical industry's graveyard. Their target isn't a new protein, but a collection of once-promising cancer drug candidates that failed because they couldn't bind their target tightly enough. OTR's approach is to design a 'molecular glue' — a small molecule that latches onto both the drug and its intended protein target, forcing a stable interaction that the original compound could never achieve on its own. This week, that ambitious rescue mission secured significant fuel, as OTR closed a $100 million venture financing round. The capital will propel its lead program, OTR-101, a glue designed to resurrect a shelved KRAS inhibitor, toward clinical testing. The company was founded three years ago by a trio of protein degradation veterans who saw an untapped niche. While most biotechs in the field aim to degrade entirely new targets, OTR's founders asked: what about the hundreds of millions already spent on compounds that almost worked? Their platform screens for small molecules that can act as synthetic adaptors, effectively turning weak binders into potent, targeted degraders. This latest funding underscores a strategic pivot within the targeted protein degradation arena. After an initial wave focused on novel E3 ligase recruiters, investor appetite is growing for approaches that de-risk development by building on known, if flawed, pharmacologies. OTR's model offers a potential shortcut, leveraging prior safety and efficacy data on the original assets. With the new funds, OTR's immediate goal is to file an IND for OTR-101 in non-small cell lung cancer by the end of 2026, setting up a critical test of whether molecular glue can indeed breathe new life into old failures.